(Q44164447)

30 November 2017

Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment (English)

1 reference

30 November 2017

1 reference

Surendra K Sharma

1

1 reference

30 November 2017

Arumugam Balamurugan

2

1 reference

30 November 2017

Pradip Kumar Saha

3

1 reference

30 November 2017

Ravindra M Pandey

4

1 reference

30 November 2017

Narinder K Mehra

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

30 November 2017

1 reference

30 November 2017

166

1 reference

30 November 2017

7

1 reference

30 November 2017

916-919

1 reference

Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.

30 November 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2108091

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2108091

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2108091

Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2108091

HLA-D region genes and susceptibility to D-penicillamine-induced myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2108091

21 January 2018

Identifiers

DOI

10.1164/RCCM.2108091

1 reference

30 November 2017

1 reference